Relacorilant 150 mg once daily (QD)

DRUG2 trials

Sponsors

Corcept Therapeutics

Conditions

Endometrial CancerFallopian Tube CancerFallopian Tube NeoplasmsOvarian CancerOvarian NeoplasmPeritoneal Neoplasms

Phase 2

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

RecruitingNCT06906341

Corcept TherapeuticsEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2025-04-11End: 2026-12-01Target: 270Updated: 2026-07-16

Phase 3

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Active, not recruitingNCT05257408

Corcept TherapeuticsFallopian Tube Neoplasms, Ovarian Neoplasm, Peritoneal Neoplasms

Start: 2022-06-29End: 2026-03-31Updated: 2025-04-16

Related Papers

Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).

Journal of Clinical Oncology2026-05-27

ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).

Journal of Clinical Oncology2025-06-043 citations

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

2025-06-0212 citations

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.

2024-07-015 citations

TP019/#1387 Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant + nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer

2023-11-011 citations

#205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer

2023-09-013 citations

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Journal of Clinical Oncology2023-06-2631 citations

Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

Journal of Clinical Oncology2022-06-086 citations